{"entity":{"id":"nct03519230","kind":"trial","name":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer","aka":[],"tldr":"A phase 3 trial of Pamiparib capsule in ovarian cancer, run by BeiGene, active and no longer recruiting.","summary":"Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer is a phase 3 interventional study registered as NCT03519230 by BeiGene, with 224 participants enrolled, started 2018-05-14 and due to reach its primary completion in 2025-12-01. Interventions recorded: Pamiparib capsule and Placebo capsule.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03519230","url":"https://clinicaltrials.gov/study/NCT03519230"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["beone"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03519230","phase":"3","setting":"A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Trial of Maintenance Treatment With BGB-290 Versus Placebo in Patients With Platinum-sensitive Recurrent Ovarian Cancer","sponsor":"BeiGene","enrolled":224,"outcomes":[]},"route":"/trials/nct03519230/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"beone","kind":"company","name":"BeOne Medicines (formerly BeiGene)","route":"/companies/beone/"}],"drug":[{"id":"pamiparib","kind":"drug","name":"Pamiparib","route":"/drugs/pamiparib/"}]}}